Varenicline for Light Smokers


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 12-005652
    NCT ID: NCT01639560
    Sponsor Protocol Number: 12-005652

About this study

The purpose of this study is to determine if varenicline is effective in treating tobacco dependence in adults who smoke 5-10 cigarettes per day.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  1. Subjects must be ≥ 18 years of age;
  2. Smokes 5 to 10 CPD for at least 6 months;
  3. Express interest in quitting smoking;
  4. Indicate ability to complete all study visits; and
  5. Provide written informed consent to participate in the study.
  6. Subject is a female subject of non-childbearing potential or a female subject of childbearing potential - who is using contraceptives and has a negative pregnancy test result;
  7. Subject is in good health as determined by the investigator;
  8. Subject has the ability to participate fully in all aspects of the study and keep scheduled appointments.

Exclusion Criteria:

  1. An active medical condition such as unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months or an untreated cardiac dysrhythmia;
  2. History of renal failure;
  3. Cancer [excluding non-melanoma skin cancer] not in remission;
  4. Psychosis or bipolar disorder;
  5. Current unstable or untreated moderate or severe depression as assessed by the CES-D;
  6. have, as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale), current non-specific suicidal thoughts, or have a lifetime history of a suicidal attempt (defined as "potentially self-injurious act committed with at least some wish to die, as a result of act.");
  7. Substance dependence other than nicotine, defined as:
    • Patient has a recent history (past month) of heavy alcohol consumption as defined by NIAAA: i. Men: More than 4 drinks on any day or 14 per week ii. Women: More than 3 drinks on any day or 7 per week.
    • Use of cocaine, heroin, club drugs (i.e., MDMA/"ecstasy"), methamphetamine, or hallucinogens (e.g., LSD) at any time during the past month.
    • Use of marijuana on a weekly basis for the past month
  8. An allergy to varenicline;
  9. Current use of a behavioral or pharmacologic tobacco dependence treatment and unwilling or unable to discontinue use;
  10. Another member of their household already participating in this study;
  11. Current treatment with another investigational drug (within 30 days of study entry).
  12. Has an unstable medical condition;
  13. Subject has untreated hypertension or baseline systolic blood pressure > 180 or diastolic > 100; and
  14. Women of child-bearing potential, or who are pregnant, lactating or likely to become pregnant during the trial and are unwilling to use an acceptable form of contraception during the medication phase will also be excluded. All female subjects of childbearing potential must have a negative pregnancy test and must agree to use approved contraception during participation in the st

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Ivana Croghan, Ph.D.

Closed for enrollment


Mayo Clinic Footer